In:
Tumori Journal, SAGE Publications, Vol. 89, No. 4 ( 2003-07), p. 385-390
Abstract:
Multiple factors contribute to transplant-related complications after high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation, including conditioning regimens, number of infused stem cells and clinical characteristics of patient at transplant. We compared the transplant-related complications of 141 patients affected with hematological malignancies with those of 109 patients with solid tumors. The total number of peripheral blood stem cell transplantations performed was 339. High-dose chemotherapy mainly consisted of melphalan-, busulphan- or thiotepa-based regimens. Despite the equal number of infused CD34 + cells, patients with a hematological malignancy showed a slower absolute neutrophil count (days to neutrophils 〉 0.5 x 10 9 /L, 10.6 ± 3.6 for hematological malignancies versus 9.1 ± 1.2 for solid tumors, P 〈 0.0001) and platelet recovery (days to platelets 〉 20 x 10 9 /L, 16.4 ± 9.8 for hematological malignancies versus 12.3 ± 4.1 for solid tumors, P 〈 0.0001) than patients with a solid tumor. A significantly higher requirement of red blood cell (3.3 ± 4.1 versus 2.0 ± 1.9, P 〈 0.0029) and platelet units (7.5_± 10.4 versus 4.2 ± 3.4, P 〈 0.0001) was observed for hematological malignancies than for solid tumors. Five graft failures were documented exclusively in patients with a hematological malignancy. Moreover, such patients displayed a longer duration of mucositis (P 〈 0.0028) and hospital stay (P 〈 0.0001), but no difference was observed in terms of febrile episodes. Transplant-related mortality was similar between the two groups. In conclusion, patients with a hematological malignancy overall have more complications than those with a solid tumor.
Type of Medium:
Online Resource
ISSN:
0300-8916
,
2038-2529
DOI:
10.1177/030089160308900407
Language:
English
Publisher:
SAGE Publications
Publication Date:
2003
detail.hit.zdb_id:
280962-X
detail.hit.zdb_id:
2267832-3